Recommended Dosing for Acute MS Relapse
For acute multiple sclerosis relapses, administer methylprednisolone 1000 mg intravenously daily for 3-5 days, without a mandatory taper. 1
Standard Dosing Regimen
The FDA-approved and most widely supported regimen is:
- Dose: 1000 mg methylprednisolone IV daily
- Duration: 3-5 days (most commonly 3 days)
- Administration: Intravenous infusion over several minutes to 30 minutes
- Taper: Not required for short courses, though some protocols include a brief oral taper
Evidence Supporting This Approach
The 1000 mg daily dose for 3 days has the strongest evidence base. A large randomized controlled trial (COPOUSEP) demonstrated that oral methylprednisolone 1000 mg daily for 3 days was non-inferior to IV administration, with 81% of oral patients and 80% of IV patients achieving improvement at 28 days 2. This suggests the total daily dose matters more than the route.
For patients with moderate to severe relapses, the FDA label specifically states: "In treatment of acute exacerbations of multiple sclerosis, daily doses of 160 mg of methylprednisolone for a week followed by 64 mg every other day for 1 month have been shown to be effective" 1. However, the shorter 3-5 day high-dose regimen (1000 mg daily) has become standard practice based on more recent evidence showing equivalent efficacy with better tolerability 2, 3.
Duration Considerations
Extending treatment beyond 5 days provides no additional clinical benefit. A study comparing 5,7, and 10 consecutive days of 1000 mg IVMP found no significant differences in IL-10/IL-12 cytokine levels or EDSS scores between groups 4. The 3-day regimen is now preferred for convenience and cost-effectiveness while maintaining full efficacy.
Lower Dose Comparison
Do not use doses below 1000 mg daily. A trial comparing 1250 mg/day versus 625 mg/day (both for 3 days) showed the standard high dose yielded superior EDSS improvement at day 7 (p=0.028), though differences equalized by day 30 5. The faster recovery with higher doses justifies the 1000 mg standard.
Route of Administration
Oral administration is an acceptable alternative to IV for patients who prefer it or lack IV access. The COPOUSEP trial established non-inferiority of oral methylprednisolone 1000 mg daily for 3 days 2. However, oral administration caused more insomnia (77% vs 64%) and may be less effective if bowel edema from MS affects absorption.
Safety Considerations
Administer doses ≥500 mg over at least 10 minutes to avoid cardiac arrhythmias and bradycardia, which have been reported with rapid infusion 1. For the standard 1000 mg dose, infusion over 30 minutes is safest when using high-dose therapy 1.
Common Pitfalls
- Avoid underdosing: The commonly prescribed methylprednisolone dose pack (84 mg total over 6 days) is grossly inadequate for MS relapses
- Don't delay treatment: Initiate within 15 days of relapse onset for optimal benefit 2, 3
- No mandatory taper needed: Short 3-5 day courses don't require tapering, unlike chronic steroid therapy
- Don't extend unnecessarily: Treatment beyond 5 days adds no benefit and increases adverse effect risk 4
Alternative Regimen for Severe Cases
For overwhelming or life-threatening presentations, the FDA label permits 30 mg/kg IV over at least 30 minutes, repeated every 4-6 hours for up to 48 hours 1. However, this is rarely necessary for typical MS relapses.